Dr. Bivas Biswas

Dr. Bivas Biswas

Senior Consultant 

18 Years of Experience

Medical Oncologist

MBBS, MD, DM

Reg. No.:60908, West Bengal Medical Council

Confirm Your Consultation With Dr. Bivas Biswas

Expert Help When You Need It – Plan in 60 Minutes

About Dr. Bivas Biswas

  • Dr. Bivas Biswas is a highly accomplished Medical Oncologist with over 18 years of extensive experience.
  • He completed his MBBS from Medical College, Kolkata, followed by an MD in Paediatrics and DM in Medical Oncology from the All India Institute of Medical Science (AIIMS), New Delhi.
  • His areas of expertise include treating all types of solid tumors, lung cancer, sarcoma, melanoma, and genitourinary cancer.
  • He specializes in providing cytotoxic chemotherapy, targeted therapy, and immunotherapy for various cancers in their early to advanced stages. 
  • During his tenure at AIIMS, Dr. Biswas earned a Gold Medal in Medical Oncology, showcasing his exceptional academic prowess.
  • He served as an Associate Professor at AIIMS, New Delhi, contributing significantly to medical education and research.
  • Dr. Biswas actively engages in clinical research, particularly focusing on lung cancer and urinary bladder cancer.
  • He is also involved in mentoring aspiring medical professionals pursuing the DNB super speciality course, which is accredited by the National Board of Education.
  • Dr. Biswas offers a comprehensive range of services catering to various oncology conditions, including gastrointestinal cancer and lung cancer.

Confirm Your Consultation With Dr. Bivas Biswas

Expert Help When You Need It – Plan in 60 Minutes

Education

  • MBBS 
  • MD (Paediatrics) - All India Institute Of Medical Sciences (AIIMS), New Delhi
  • DM (Medical Oncology), All India Institute Of Medical Sciences (AIIMS), New Delhi

OPD Schedule Of Dr. Bivas Biswas

Book Appointment
  • Clinical Predictors and Prognostic Model for Pediatric Lymphoblastic Lymphoma Treated With Uniform BFM90 Protocol: A Single-Center Experience of 65 Patients From Asia
  • Metronomic therapy in metastatic castrate-resistant prostate cancer: Experience from a tertiary cancer care center
  • A review on adverse event profiles of epidermal growth factor receptor-tyrosine kinase inhibitors in nonsmall cell lung cancer patients
  • Pretreatment neutrophilto lynphocyte ratio in ewing sarcoma family of tumors: An analysis of 570 patients.
  • Role of High Dose Radiotherapy for Locally Advanced Pancreatic Cancer – a Single Centre Experience from Eastern India
  • Cytoreductive Nephrectomy in Metastatic Renal Cell Carcinoma in the Era of Targeted Therapy: Scientifically Relevant or Natural Selection?
  • 287P Metronomic cyclophosphamide in metastatic castrate resistant prostate cancer: Experience from a tertiary cancer care center
  • 506PD Ewing Sarcoma family tumors of vertebral column treated with uniform chemotherapy protocols: Experience from a tertiary cancer care center
  • 506PD Ewing Sarcoma family tumors of vertebral column treated with uniform chemotherapy protocols: Experience from a tertiary cancer care center
  • Hypoalbuminemia and High WBC are Poor Predictors of Survival in Head and Neck Ewing Sarcoma Family of Tumors: An Updated Analysis of 59 Patients
  • Pretreatment Neutrophil to Lymphocyte Ratio Predicts Event Free and Overall Survival in Patients of Childhood T Cell Non-Hodgkin Lymphoma